Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)
Status:
Completed
Trial end date:
2011-11-11
Target enrollment:
Participant gender:
Summary
Use of PTH (1-84) a recombinant hormone in 25 µg or 50 µg doses for the treatment of adults
with hypoparathyroidism. The use of PTH (1-84) should result in a decrease of calcium and
vitamin D supplements.